作为 ALK TK 抑制剂的新型泊沙康唑衍生物的合成、硅学研究和体外细胞毒性评价

IF 2.8 3区综合性期刊 Q2 MULTIDISCIPLINARY SCIENCES

Journal of Taibah University for Science Pub Date : 2024-04-03 DOI:10.1080/16583655.2024.2336674

Rahul D. Jawarkar, Praveen Sharma, Sachin Jain, Umang Shah, Magdi EA Zaki, Sami A Al-Hussain, Suraj Mali, Chin-Hung Lai, Vijay H. Masand, Vivek T Humne

{"title":"作为 ALK TK 抑制剂的新型泊沙康唑衍生物的合成、硅学研究和体外细胞毒性评价","authors":"Rahul D. Jawarkar, Praveen Sharma, Sachin Jain, Umang Shah, Magdi EA Zaki, Sami A Al-Hussain, Suraj Mali, Chin-Hung Lai, Vijay H. Masand, Vivek T Humne","doi":"10.1080/16583655.2024.2336674","DOIUrl":null,"url":null,"abstract":"Oncology research progresses, yet cancer remains the largest medical need. The use of a medication with an accessible lead molecule shows great potential for long-term cancer therapy. It may help t...","PeriodicalId":17100,"journal":{"name":"Journal of Taibah University for Science","volume":"2011 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis, in silico studies and in vitro cytotoxicity evaluation of novel posaconazole derivative as a ALK TK inhibitor\",\"authors\":\"Rahul D. Jawarkar, Praveen Sharma, Sachin Jain, Umang Shah, Magdi EA Zaki, Sami A Al-Hussain, Suraj Mali, Chin-Hung Lai, Vijay H. Masand, Vivek T Humne\",\"doi\":\"10.1080/16583655.2024.2336674\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Oncology research progresses, yet cancer remains the largest medical need. The use of a medication with an accessible lead molecule shows great potential for long-term cancer therapy. It may help t...\",\"PeriodicalId\":17100,\"journal\":{\"name\":\"Journal of Taibah University for Science\",\"volume\":\"2011 1\",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-04-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Taibah University for Science\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1080/16583655.2024.2336674\",\"RegionNum\":3,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Taibah University for Science","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1080/16583655.2024.2336674","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

肿瘤学研究在不断进步，但癌症仍然是最大的医疗需求。使用具有易得先导分子的药物显示出长期治疗癌症的巨大潜力。它可能有助于治疗癌症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Synthesis, in silico studies and in vitro cytotoxicity evaluation of novel posaconazole derivative as a ALK TK inhibitor

Oncology research progresses, yet cancer remains the largest medical need. The use of a medication with an accessible lead molecule shows great potential for long-term cancer therapy. It may help t...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Taibah University for Science MULTIDISCIPLINARY SCIENCES-

CiteScore

6.60

自引率

6.10%

发文量

102

审稿时长

19 weeks

期刊介绍： Journal of Taibah University for Science (JTUSCI) is an international scientific journal for the basic sciences. This journal is produced and published by Taibah University, Madinah, Kingdom of Saudi Arabia. The scope of the journal is to publish peer reviewed research papers, short communications, reviews and comments as well as the scientific conference proceedings in a special issue. The emphasis is on biology, geology, chemistry, environmental control, mathematics and statistics, nanotechnology, physics, and related fields of study. The JTUSCI now quarterly publishes four issues (Jan, Apr, Jul and Oct) per year. Submission to the Journal is based on the understanding that the article has not been previously published in any other form and is not considered for publication elsewhere.